Role of platelets in neurodegenerative diseases: A universal pathophysiology

International Journal of Neuroscience

Volumn 123, Issue 5, 2013, Pages 287-299

  Behari, Madhuri ^a   Shrivastava, Mohita ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Biochemical changes; Mitochondria; Molecular changes; Neurodegenerative diseases; Platelets; Ultrastructural alterations

Indexed keywords

ADENOSINE DIPHOSPHATE; AMYLOID BETA PROTEIN; CHEMOKINE; COLLAGEN; CYCLOOXYGENASE 2; CYTOCHROME C OXIDASE; DJ 1 PROTEIN; DOPAMINE; GLUTAMIC ACID; GLUTAMINASE; GLYCOGEN SYNTHASE KINASE 3BETA; GLYCOPROTEIN; MITOCHONDRIAL DNA; NEUROTRANSMITTER; PHOSPHOLIPASE A; SECRETASE; SELEGILINE; SEROTONIN; SYNUCLEIN; THROMBIN; THROMBOSPONDIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; ARTICLE; EXCITOTOXICITY; HUMAN; HUNTINGTON CHOREA; MEDICAL RESEARCH; MITOCHONDRION; MULTIPLE SCLEROSIS; PARKINSON DISEASE; SEROTONINERGIC NERVE CELL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE STRUCTURE;

ANIMALS; BIOLOGICAL MARKERS; BLOOD PLATELETS; HUMANS; NEURODEGENERATIVE DISEASES;

EID: 84876176479     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2012.751534     Document Type: Article

References (124)

1. Fuse I. Disorders of platelet function. Clin RevOncol Hematol 1996;22:1-25.
2. Alvaro C, Dimsdale JE. Platelets and psychiatry: lessons learned from old and new studies. Psychosom Med 2000;62:326-36.
3. Pretorius E, Oberholzer HM, Smit E, et al. Ultrastructural changes in platelet aggregates of HIV patients: a scanning electron microscopic study. Ultrastruct Pathol 2008;32:75-9.
4. Pretorius E, Oberholzer HM. Ultrastructural changes of platelets and fibrin networks in human asthma: a qualitative case. Ultrastruct Pathol Blood Coagul Fibrinolysis 2009;20:146-9.
5. Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost 2011 May;105 (Suppl 1):S13-33. Review.
6. Shrivastava M, Taposh K. Das, Madhuri Behari, et al. Ultrastructural variations in platelets and platelet mitochondria - a novel feature in amyotrophic lateral sclerosis. Ultrastruct Pathol 2011;35(2):52-9.
7. Shrivastava M, Vivekanandhan S, Behari M, et al. Mitochondrial perturbance and execution of apoptosis in platelet mitochondria of patients with amyotrophic lateral sclerosis. Int J Neurosci. 2011;121(3):149-58.
8. Mohita S, Vivekanandhan S. An Insight into ultrastructural andmorphological alterations of platelets in neurodegenerative diseases (review). Ultrastruct Pathol 2011;35(3):110-6.
9. Pignatelli P, Pulcinelli FM, Lenti L, et al. Hydrogen peroxide is involved in collagen-induced platelet activation. Blood 1998;91(2):484-90.
10. Seno T, Inoue N, Gao D, et al. Involvement of NADH/NADPH oxidase in human platelet ROS production. Thrombosis Res 2001;103(5):399-409.
11. Rosado JA, Redondo PC, Salido GM, et al. Hydrogen peroxide generation induces pp60src activation in human platelets: evidence for the involvement of this pathway in store-mediated calcium entry. J Biol Chem 2004;279(3):1665-75.
12. Swerdlow RH, Parks JK, Cassarino DS, et al. Mitochondria in sporadic amyotrophic lateral sclerosis. Exp Neurol 1998 Sep;153(1):135-42.
13. Swerdlow RH. Mitochondria in cybrids containing mtDNA fro from persons with mitochondriopathies. J Neurosci Res 2007;85:3416-28.
14. Kile BT. The role of the intrinsic apoptotic pathway in platelet life and death. J Thromb Haemost 2009 Jul 7(Suppl 1):214-7.
15. Perrotta PL, Perrotta CL, Snyder EL. Apoptotic activity in stored human platelets. Transfusion 2003 Apr;43(4):526- 35.
16. Lin KH, Chang HC, Lu WJ, et al. Comparison of the relative activities of inducing platelet apoptosis stimulated by various platelet-activating agents. Platelets 2009 Dec;20(8):575-81.
17. Ferraro-Peyret C, Quemeneur L, Flacher M, et al. Caspaseindependent phosphatidylserine exposure during apoptosis of primary T lymphocytes. J Immunol 2002 Nov 1;169(9):4805-10.
18. Ferrarese C, Sala G, Riva R, et al. Decreased platelet glutamate uptake in patients with amyotrophic lateral sclerosis. Neurology 2001 Jan 23;56(2):270-2.
19. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927-9.
20. Fritsma GA. Managing the bleeding patient. Clin Lab Sci (2003) Spring;16(2):107-10.
21. Li QX, Campbell BC, McLean CA, et al. Platelet alpha- and gamma-synucleins in Parkinson's disease and normal control subjects. J Alzheimers Dis 2002 Aug;4(4):309-15.
22. Michell AW, Luheshi LM, Barker RA. Skin and platelet alphasynuclein as peripheral biomarkers of Parkinson's disease. Neurosci Lett 2005 Jun 24;381(3):294-8.
23. Nakai M, Fujita M, Waragai M, et al. Expression of alphasynuclein, a presynaptic protein implicated in Parkinson's disease, in erythropoietic lineage. Biochem Biophys Res Commun 2007 Jun 22;358(1):104-10.
24. Sala G, Brighina L, Saracchi E, et al. Vesicular monoamine transporter 2 mRNA levels are reduced in platelets from patients with Parkinson's disease. J Neural Transm 2010 Sep;117(9):1093-8.
25. Vignini A, Sartini D, Morganti S, et al. Platelet amyloid precursor protein isoform expression in Alzheimer's disease: evidence for peripheral marker. Int J Immunopathol Pharmacol 2011 Apr-Jun;24(2):529-34.
26. ShiM, ZabetianCP, Hancock AM, et al. Significance and confounders of peripheralDJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett 2010 Aug 9;480(1):78-82.
27. Kumar AM, Sevush S, Kumar M, et al. Peripheral serotonin in Alzheimer's disease. Neuropsychobiology 1995;32(1): 9-12.
28. Kumar AM, Kumar M, Sevush S, et al. Serotonin uptake and its kinetics in platelets of women with Alzheimer's Disease. Psychiatry Res 1995 Nov 29;59(1-2):145-50.
29. Dupuis Luc, Spreux-Varoquaux O, Bensimon G, et al. Platelet serotonin level predicts survival in amyotrophic lateral sclerosis. PLoS One 2010 Oct 13;5(10):e13346.
30. MachaczkaM, Rucinska M, Skotnicki AB, Jurczak W. Parkinson's syndrome preceding clinical manifestation of Gaucher's disease. Am J Hematol 1999 Jul;61(3):216-7.
31. Agusta VE, Gillenwater JY, Mann JD. Postoperative bleeding associated with levodopa therapy. J Urol 1973 Nov;110(5):574-6.
32. Bembi B, Zambito Marsala S, Sidransky E, et al. Gaucher's disease with Parkinson's disease: clinical and pathological aspects. Neurology 2003 Jul 8;61(1):99-101.
33. Guggenbuhl P, Grosbois B, Chalés G. Gaucher disease. Joint Bone Spine 2008 Mar;75(2):116-24.
34. SheremataWA, Jy W, Horstman LL, et al. Evidence of platelet activation in multiple sclerosis. J Neuroinflammation 2008 Jun 27;5:27.
35. Swerdlow RH, Parks JK, Cassarino DS, et al. Characterization of cybrid cell lines containing mtDNA from Huntington's disease patients. Biochem Biophys Res Commun 1999 Aug 11;261(3):701-4.
36. BinderDR, DunnWHJr, Swerdlow RH. Mitochondrion 2005 Aug;5(4):255-65.
37. Ferrick DA, Neilson A, Beeson C. et al. Advances in measuring cellular bioenergetics using extracellular flux. Drug Discov Today 2008;13:268-74.
38. Verhoeven AJ, Verhaar R, Gouwerok EG, de Korte D. The mitochondrial membrane potential in human platelets: a sensitive parameter for platelet quality. Transfusion 2005 Jan;45(1):82-9.
39. Picker SM, Schneider V, Oustianskaia L, Gathof BS. Cell viability during platelet storage in correlation to cellular metabolism after different pathogen reduction technologies. Transfusion 2009 Nov;49(11):2311-8.
40. Swerdlow RH, Parks JK, Cassarino DS, et al. Cybrids in Alzheimer's disease: a cellular model of the disease? Neurology 1997;49:918-25.
41. Xu J, Shi C, Li Q, et al. Mitochondrial dysfunction in platelets and hippocampi of senescence accelerated mice. J Bioenerg Biomembr 2007;39:195-202.
42. Swerdlow RH, Parks JK, Pattee G, Parker WD Jr. Role of mitochondria in amyotrophic lateral sclerosis. Amyotroph Lateral Sclerosis and Other Motor Neuron Disorders 2000;1:185-90.
43. Swerdlow RH. Mitochondrial DNA-related mitochondrial dysfunction in neurodegenerative diseases. Arch Pathol Lab Med 2002 Mar;126(3):271-80.
44. Trimmer PA, Swerdlow RH, Parks JK, et al. Abnormal mitochondrialmorphology in sporadic Parkinson's and Alzheimer's disease cybrid cell lines. Exp Neurol 2000;162:37-50.
45. Trimmer PA, Keeney PM, Borland MK, et al. Mitochondrial abnormalities in cybrid cell models of sporadic Alzheimer's disease worsen with passage in culture. Neurobiol Disease 2004;15:29-39.
46. Swerdlow RH. Brain aging, Alzheimer's disease, and mitochondria. Biochim Biophys Acta 2011 Dec;1812(12):1630-9. Epub 2011 Sep 2. Review.
47. Humphrey PP, Hartig P, Hoyer D. A proposed new nomenclature for 5-HT receptors. Trends Pharmacol Sci 1993;14:233-6.
48. Skop BP, Finkelstein JA, Mareth TR. The serotonin syndrome associated with paroxetine, an over-the-counter remedy, and vascular disease: a case report and review. Am J Emerg Med 1994;12:642-4.
49. Horstman LL, Jy W, Ahn YS, et al. Role of platelets in neuroinflammation: a wide-angle perspective. Neuroinflammation 2010 Feb 3;7:10. Review.
50. Lesch KP, Wolozin BL, Murphy DL, Reiderer P. Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem 1993;60:2319-22.
51. Mimica N, Muck-Seler D, Pivac N, et al. Platelet serotonin and monoamine oxidase in Alzheimer's disease with psychotic features. Coll Antropol 2008;Jan;32 (Suppl 1):119-22.
52. Perris C, EisemannM, Von Knorring L, et al. Personality traits and monoamine oxidase activity in platelets in depressed patients. Neuropsychobiology 1984;12:201-5.
53. Begni B, Tremolizzo L, D'Orlando C, et al. Substrate-induced modulation of glutamate uptake in human platelets. Br J Pharmacol 2005 Jul;145(6):792-9.
54. Bos IW, Hoogland G, Meine Jansen CF, et al. Increased glutamine synthetase but normal EAAT2 expression in platelets of ALS patients. Neurochem Int 2006 Mar;48(4):306-11.
55. Tremolizzo L, Beretta S, Ferrarese C. Peripheral markers of glutamatergic dysfunction in neurological diseases: focus on ex vivo tools. Crit Rev Neurobiol 2004;16(1-2):141-6. Review.
56. Hoogland G, Bos IW, Kupper F, et al. Thrombin-stimulated glutamate uptake in human platelets is predominantly mediated by the glial glutamate transporter EAAT2. Neurochem Int 2005 Dec;47(7):499-506.
57. Friedlander RobertM. Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 2005;348:1365-75.
58. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770-6.
59. Yuan J, Yankner BA. Apoptosis in the nervous system. Nature 2000;407:802-9.
60. Barber SC, Mead RJ, Shaw PJ. Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. Biochim Biophys Acta 2006 Nov-Dec;1762(11-12):1051-67.
61. BealMFMitochondria, free radicals, and Neurodegeneration. Curr Opin Neurobiol 1996;6(5), 661-666.
62. Menzies FM, Ince PG, Shaw PJ. Mitochondrial involvement in amyotrophic lateral sclerosis. Neurochem Int 2002 May;40(6):543-51.
63. Leytin V, Allen DJ, Mutlu A, et al. Platelet activation and apoptosis are different phenomena: evidence from the sequential dynamics and the magnitude of responses during platelet storage. Br J Haematol 2008 Jul;142(3):494-7.
64. Leytin V, Allen DJ, Mykhaylov S, et al. Pathologic high shear stress induces apoptosis events in human platelets. Biochem Biophys Res Commun 2008 Jul 23;320(2):303-10.
65. Leytin V, Allen DJ, Mutlu A, et al. Mitochondrial control of platelet apoptosis: effect of cyclosporin A, an inhibitor of the mitochondrial permeability transition pore. J Lab Invest 2009 Apr;89(4):374-84.
66. White MJ, Schoenwaelder SM, Josefsson EC, et al. Caspase-9 mediates the apoptotic death of megakaryocytes and platelets, but is dispensable for their generation and function. Blood 2012 May 3;119(18):4283-90.
67. Koopman C, Reutelingsperger CPM, Kuijten GAM, et al. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994;84:1415-20.
68. Seghatchian J, Krailadsiri P. Platelet storage lesion and apoptosis: are they related? Transfus Apher Sci 2001 Feb;24(1):103-5.
69. Lages B, Weiss HJ. Enhanced increases in cytosolic Ca2+ in ADP-stimulated platelets from patients with delta-storage pool deficiency-a possible indicator of interactions between granule-bound ADP and the membrane ADP receptor. Thromb Haemost 1997 Feb;77(2):376-82.
70. Pacchiarini L, Zucchella M, Eynard AR, Grignani G. Tumor cell induced platelet aggregation and intraplatelet calcium ion movements. Platelets 1993;4:275-279.
71. Cattaneo M, Hunt BJ, Van Aken H, et al. Guidelines for the diagnosis and management of von Willebrand's disease. Eur J Anaesthesiol Suppl 1997 Mar;14:23.
72. Pearson TA, LaCava J,Weil HF. Epidemiology of thrombotichemostatic factors and their associations with cardiovascular disease. Am J Clin Nutr 1997 May;65 (5 Suppl):1674S-82S.
73. Komiya T, Kudo M, Urabe T, Mizuno Y. Compliance with antiplatelet therapy in patients with ischemic cerebrovascular disease. Assessment by platelet aggregation testing. Stroke 1994 Dec;25(12):2337-42.
74. Stellos K, Panagiota V, Kogel A, et al. Predictive value of platelet activation for the rate of cognitive decline in Alzheimer's disease patients. J Cereb Blood Flow Metab 2010;30:1817-20.
75. Kiktenko AI, Zlobina GP, Brusov OS, Zakharova MN. Structure of peripheral blood platelets surface in patients with amyotrophic lateral sclerosis and multiple sclerosis. Zh Nevrol Psikhiatr Im S S Korsakova 2005;105(3):40-2.
76. Lim KM, Kim HH, Bae ON, et al. Inhibition of platelet aggregation by 1-methyl-4-phenyl pyridinium ion (MPP+) through ATP depletion: evidence for the reduced platelet activities in Parkinson's disease. Platelets 2009 May;20(3):163-70.
77. Pretorius E. The role of platelet and fibrin ultrastructure in identifying disease patterns. Pathophysiol Haemost Thromb 2008;36(5):251-8.
78. Factor SA, Ortof E, Dentinger MP, et al. Platelet morphology in Parkinson's disease: an electron microscopic study. J Neurol Sci 1994 Mar;122(1):84-9.
79. Hochstrasser T, Marksteiner J, Defrancesco M, et al. Two blood monocytic biomarkers (CCL15 and p21) combined with the mini-mental state examination discriminate Alzheimer's disease patients from healthy subjects. Dement Geriatr Cogn Dis Extra 2011 Jan;1(1):297-309.
80. Ehrlich D, Hochstrasser T, Humpel C. Effects of oxidative stress on amyloid precursor protein processing in rat and human platelets. Platelets 2012 Mar 2. [Epub ahead of print].
81. Smirnova IV, Festoff BW. Alterations in serum thrombospondin in patients with amyotrophic lateral sclerosis. JNeurol Sci 1994 Dec 20;127(2):207-13.
82. Blandini F, Mangiagalli A, Cosentino M, et al. Peripheral markers of apoptosis in Parkinson's disease: the effect of dopaminergic drugs. AnnNYAcad Sci 2003 Dec;1010:675-8.
83. Gotz ME, Gerstner A, Harth R, et al. Altered redox state of platelet coenzyme Q10 in Parkinson's Disease. J Neural Transm 2000;107(1):41-8.
84. Behari M. Abraham S, Soundararajan CC, Vivekanandhan S. Erythrocyte antioxidant enzymes in Parkinson's disease. Indian J Med Res 2005;Feb;121(2):111-5.
85. Hargreaves IP, Lane A, Sleiman PM. The coenzyme Q10 status of the brain regions of Parkinson's disease patients. Neurosci Lett 2008 Dec 5;447(1):17-9.
86. Laske C, Leyhe T, Stransky E, et al. Association of plateletderived soluble glycoprotein VI in plasma with Alzheimer's disease. J Psychiatr Res 2008 Jul;42(9):746-51. Epub 2007 Sep 12.
87. Mancuso M, Orsucci D, LoGerfo A, et al. Clinical features and pathogenesis of Alzheimer's disease: involvement of mitochondria and mitochondrial DNA. Adv Exp Med Biol 2010;685:34-44.
88. Parker WD Jr., Parks J, Filley CM, Kleinschmidt-DeMasters BK. Electron transport chain defects in Alzheimer's disease brain. Neurology 1994;44, 1090-6.
89. ParkerWDJr., Parks JK, Cytochrome c oxidase in Alzheimer's disease brain: purification and characterization. Neurology 1994;45:482-6.
90. Forlenza OV, Torres CA, Talib LL, et al. Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer's disease. J Psychiatr Res 2011 Feb;45(2):220-4.
91. Husain M, Shukla R, Dikshit M, et al. Altered platelet monoamine oxidase-B activity in idiopathic Parkinson's disease. Neurochem Res 2009 Aug;34(8):1427-32.
92. Vielhaber S, Kunz D, Winkler K, et al. Mitochondrial DNA abnormalities in skeletal muscle of patients with sporadic amyotrophic lateral sclerosis. Brain 2000;123:1339-48.
93. Wiedemann FR, Winkler K, Kuznetsov AV, et al. Impairment of mitochondrial function in skeletal muscle of patients with amyotrophic lateral sclerosis. J Neurol Sci 1998;156:65-72.
94. Nakano Y, Hirayama K, Terao K. Hepatic ultrastructural changes and liver dysfunction in amyotrophic lateral sclerosis. Arch Neurol 1987 Jan;44(1):103-6.
95. Curti, D., Malaspina, A., Facchetti, G., et al. Amyotrophic lateral sclerosis: oxidative energy metabolism and calcium homeostasis in peripheral blood lymphocytes. Neurology 1996;47:1060-4.
96. Wong PC, Pardo CA, Borchelt DR, et al. An adverse property of a familiar ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995;14:1105-16.
97. Kong J, Xu Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci 1998;18:3241-50.
98. Rao JS, Hantai D, Festoff BW. Thrombospondin, a platelet alpha-granule and matrix glycoprotein, is increased in muscle basement membrane of patients with amyotrophic lateral sclerosis. J Neurol Sci 1992 Nov;113(1):99-107.
99. Domingues AF, Ardúino DM, Esteves AR, et al. Mitochondria and ubiquitin-proteasomal system interplay: relevance to Parkinson's disease. Free Radic Biol Med 2008;Sep 15;45(6):820-5.
100. Schapira AH, Gu M, Taanman JW, et al. Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann Neurol 1998b Sep;44(3 Suppl 1):S89-98.
101. Varghese M, Pandey M, Samanta A, et al. Reduced NADH coenzyme Q dehydrogenase activity in platelets of Parkinson's disease, but not Parkinson plus patients, from an Indian population. J Neurol Sci 2009 Apr 15;279(1-2):39-42.
102. Esteves AR, Domingues AF, Ferreira IL, et al. Mitochondrial function in Parkinson's disease cybrids containing an NT-2 neuron-like nuclear background. Mitochondrion 2008 Jun;8(3):219-28.
103. Obeid R, Schadt A, Dillmann U, et al. Methylation status and neurodegenerative markers in Parkinson disease. Clin Chem 2009 Oct;55(10):1852-60.
104. George S, Mok SS, Nurjono M, et al. α-Synuclein transgenic mice reveal compensatory increases in Parkinson's disease-associated proteins DJ-1 and parkin and have enhanced α-synuclein and PINK1 levels after rotenone treatment. J Mol Neurosci 2010 Oct;42(2):243-54. Epub 2010 May 13.
105. Ferrarese C, Zoia C, Pecora N, et al. Reduced platelet glutamate uptake in Parkinson's disease. J Neural Transm 1999;106(7-8):685-92.
106. Rudolf J, Grond M, Neveling M, Heiss WD. Clozapineinduced agranulocytosis and thrombopenia in a patient with dopaminergic psychosis. J Neural Transm 1997;104(11-12):1305-11.
107. Guggenbuhl P, Grosbois B, Chalés G. Gaucher disease. Joint Bone Spine 2008 Mar;75(2):116-24.
108. Borroni B, Agosti C, Marcello E, et al. Blood cell markers in Alzheimer disease: amyloid precursor protein form ratio in platelets. Exp Gerontol 2010 Jan;45(1):53-6.
109. Jaremo P, Milovanovic M, Buller C, et al. Low-density platelet populations demonstrate low in vivo activity in sporadic Alzheimer disease. Platelets 2012;23(2):116- 20.
110. Hajimohammadreza I, Brammer MJ, Eagger S, et al. Platelet and erythrocyte membrane changes in Alzheimer's disease. Biochim Biophys Acta 1990 Jun 27;1025(2):208-14.
111. Casoli T, Di Stefano G, Balietti M, et al. Peripheral inflammatory biomarkers of Alzheimer's disease: the role of platelets. Biogerontology 2010 Oct;11(5):627-33. Epub 2010 May 9. Review.
112. Selfridge JE, E L, Lu J, Swerdlow RH. Role of mitochondrial homeostasis and dynamics in Alzheimer's disease. Neurobiol Dis 2012 [Epub ahead of print].
113. Parker WD Jr., Filley CM, Parks JK. Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 1990;40: 1302-3.
114. Kish SJ, Bergeron C, Rajput A, et al. Brain cytochrome oxidase in Alzheimer's disease. J Neurochem 1992 Aug;59(2): 776-9.
115. Wong-Riley M, Antuono P, Ho KC, et al. Cytochrome oxidase in Alzheimer's disease: biochemical, histochemical, and immunohistochemical analyses of the visual and other systems. Vision Res 1997 Dec;37(24):3593-608.
116. Spanevello RM, Mazzanti CM, Bagatini M, et al. Activities of the enzymes that hydrolyze adenine nucleotides in platelets from multiple sclerosis patients. J Neurol 2010 Jan;257(1):24-30. Epub 2009 Jul 24.
117. Markianos M, Panas M, Kalfakis N, Vassilopoulos D. Platelet monoamine oxidase activity in subjects tested for Huntington's disease gene mutation. J Neural Transm 2004 Apr;111(4):475-83. Epub 2004 Feb 4.
118. Mangano RM, Schwarcz R. Platelet glutamate and aspartate uptake in Huntington's disease. J Neurochem 1981 Oct;37(4):1072-4.
119. Mangano RM, Schwarcz R. Huntington's disease. Glutamate and aspartate metabolism in blood platelets. J Neurol Sci 1982 Mar;53(3):489-500.
120. Reilmann R, Rolf LH, Lange HW. Huntington's disease: the neuroexcitotoxin aspartate is increased in platelets and decreased in plasma. J Neurol Sci 1994 Dec 1;127(1):48-53.
121. Reilmann R, Rolf LH, Lange HW. Huntington's disease: Nmethyl- D-aspartate receptor coagonist glycine is increased in platelets. Exp Neurol 1997 Apr;144(2):416-9.
122. Varani K, Gessi S, Merighi S, et al. Alteration of A(3) adenosine receptors in human neutrophils and low frequency electromagnetic fields. Biochem Pharmacol 2003 Nov 15;66(10):1897-906.
123. Maglione V, Giallonardo P, Cannella M, et al. Adenosine A2A receptor dysfunction correlates with age at onset anticipation in blood platelets of subjects with Huntington's disease. Am J Med Genet B Neuropsychiatr Genet 2005 Nov 5;139B (1):101-5.
124. Ferreira IL, NascimentoMV, RibeiroM, et al. Mitochondrialdependent apoptosis in Huntington's disease human cybrids. Exp Neurol 2010 Apr;222(2):243-55.